GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies

Background Antibody–drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional endogenous antitumor immune responses. Here, we characterized the immunomodulatory prope...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul M Sondel, Amy K Erbe, Daniel Martinez, Samantha N Buongervino, Kristopher R Bosse, Guillem Pascual-Pasto, Brendan McIntyre, Rawan Shraim, Doncho V Zhelev, Shakhnozakhon Sadirova, Anna M Giudice, Laura Garcia-Gerique, Dimiter S Dimitrov
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/12/e004704.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/12/e004704.full

Similar Items